Cash-strapped biotechs. According to a new report, venture capitalists are pouring money into biotechnology, but don’t get too excited just yet. A lot of that is going to late-stage companies working on drugs that were developed years ago. Last year, early-stage biotechs and medical device companies saw the lowest amount of investment activity in 15 years, according to new data.
The State of Healthcare. As the State of the Union address nears, speculation has begun on how President Obama will outline his strategy on healthcare. Last year, he called for a bipartisan collaboration to improve the healthcare reform law. This year, with a Supreme Court ruling looming, battle lines are drawn more sharply.
To read the full, original article click on this link: Don’t be fooled. Funding for early-stage biotechs is suffering (Morning Read)
